Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway

Nutrition and Cancer

Volumn 64, Issue 6, 2012, Pages 864-870

  Li, Nan ^a   Bu, Xiaodong ^a   Tian, Xiaoqiang ^a   Wu, Peng ^a   Yang, Lin ^a   Huang, Peilin ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN CACO 2; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; CACO-2 CELLS; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX, TYPE I; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 84865274702     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.701704     Document Type: Article

References (41)

1. Warburg, O. 1956. On the origin of cancer cells. Science, 123: 309-314.
2. Sugino, T, Baba, K, Hoshi, N, Aikawa, K, Yamaguchi, O. 2011. Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor of prognosis of cancer patients. Med Mol Morphol, 44: 146-150.
3. Silva, S D, Cunha, I W, Younes, R N, Soares, F A, Kowalski, L P. 2010. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. Oral Dis, 16: 774-780.
4. Flavin, R, Peluso, S, Nguyen, P L, and, Loda, M. 2010. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol, 6: 551-562.
5. Liu, J, and, Brown, R E. 2011. Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin. Int J Clin Exp Pathol, 4: 755-764.
6. Uddin, S, Jehan, Z, Ahmed, M, Alyan, A, Al-Dayel, F. 2011. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis. Mol Med, 17: 635-645.
7. Wakil, S J. 1989. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry, 28: 4523-4530. (Pubitemid 19151020)
8. Maier, T, Jenni, S, and, Ban, N. 2006. Architecture of mammalian fatty acid synthase at 4.5 A resolution. Science, 311: 1258-1262. (Pubitemid 43334709)
9. Menendez, J A, and, Lupu, R. 2006. Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care, 9: 346-357. (Pubitemid 44101969)
10. Migita, T, Ruiz, S, Fornari, A, Fiorentino, M, Priolo, C. 2009. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst, 101: 519-532.
11. Uddin, S, Hussain, A R, Ahmed, M, Abubaker, J, Al-Sanea, N. 2009. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am J Gastroenterol, 104: 1790-1801.
12. Ishimura, N, Amano, Y, Sanchez-Siles, A A, Fukuhara, H, Takahashi, Y. 2011. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis. J Clin Gastroenterol, 45: 665-672.
13. Kumar-Sinha, C, Ignatoski, K W, Lippman, M E, Ethier, S P, and, Chinnaiyan, A M. 2003. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res, 63: 132-139. (Pubitemid 36070431)
14. Jemal, A, Siegel, R, Ward, E, Hao, Y, Xu, J. 2008. Cancer statistics, 2008. CA Cancer J Clin, 58: 71-96. (Pubitemid 351521864)
15. Huang, P L, Zhu, S N, Lu, S L, Dai, Z S, and, Jin, Y L. 2000. Inhibitor of fatty acid synthase induced apoptosis in human colonic cancer cells. World J Gastroenterol, 6: 295-297. (Pubitemid 30223620)
16. Livak, K J, and, Schmittgen, T D. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25: 402-408. (Pubitemid 34164012)
17. Alo, P L, Amini, M, Piro, F, Pizzuti, L, Sebastiani, V. 2007. Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic cancer. Anticancer Res, 27: 2523-2527. (Pubitemid 47228098)
18. Silva, S D, Cunha, I W, Rangel, A L, Jorge, J, Zecchin, K G. 2008. Differential expression of fatty acid synthase (FAS) and ErbB2 in nonmalignant and malignant oral keratinocytes. Virchows Arch, 453: 57-67.
19. da Silva, S D, Cunha, I W, Nishimoto, I N, Soares, F A, Carraro, D M. 2009. Clinicopathological significance of ubiquitin-specific protease 2a (USP2a), fatty acid synthase (FASN), and ErbB2 expression in oral squamous cell carcinomas. Oral Oncol, 45: e134-e139.
20. Sehdev, A S, Kurman, R J, Kuhn, E, and, Shih, IeM. 2010. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol, 23: 844-855.
21. Zhang, D, Tai, L K, Wong, L L, Chiu, L L, Sethi, S K. 2005. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics, 4: 1686-1696. (Pubitemid 41749262)
22. Menendez, J A, Oza, B P, Colomer, R, and, Lupu, R. 2005. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol, 26: 1507-1515.
23. Carey, L A. 2012. Breast cancer: HER2-a good addiction. Nat Rev Clin Oncol,. [Epub ahead of print]
24. Menendez, J A, Vellon, L, Mehmi, I, Oza, B P, Ropero, S. 2004. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA, 101: 10715-10720. (Pubitemid 38955808)
25. Vazquez-Martin, A, Colomer, R, Brunet, J, Lupu, R, and, Menendez, J A. 2008. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif, 41: 59-85. (Pubitemid 351147647)
26. Bandyopadhyay, S, Pai, S K, Watabe, M, Gross, S C, Hirota, S. 2005. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene, 24: 5389-5395. (Pubitemid 43080109)
27. Wang, H Q, Altomare, D A, Skele, K L, Poulikakos, P I, Kuhajda, F P. 2005. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian cancer cells. Oncogene, 24: 3574-3582. (Pubitemid 40756227)
28. Chiang, C T, Way, T D, Tsai, S J, and, Lin, J K. 2007. Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett, 581: 5735-5742.
29. Toker, A, and, Cantley, L C. 1997. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature, 387: 673-676. (Pubitemid 27270600)
30. Ghigo, A, Morello, F, Perino, A, and, Hirsch, E. 2012. Phosphoinositide 3-kinases in health and disease. Subcell Biochem, 58: 183-213.
31. Franke, T F, Kaplan, D R, and, Cantley, L C. 1997. PI3K: downstream AKTion blocks apoptosis. Cell, 88: 435-437. (Pubitemid 27154408)
32. Dituri, F, Mazzocca, A, Giannelli, G, and, Antonaci, S. 2011. PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol,: 947858
33. Kennedy, A L, Adams, P D, and, Morton, J P. 2011. Ras, PI3K/Akt and senescence: Paradoxes provide clues for pancreatic cancer therapy. Small Gtpases, 2: 264-267.
34. Hafner, C, Houben, R, Baeurle, A, Ritter, C, Schrama, D. 2012. Activation of the PI3K/AKT Pathway in Merkel Cell Carcinoma. PLoS One, 7: e31255
35. Riggio, M, Polo, M L, Blaustein, M, Colman-Lerner, A, Lthy, I. 2012. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer. Carcinogenesis, 33: 509-518.
36. Yaguchi, S, Fukui, Y, Koshimizu, I, Yoshimi, H, Matsuno, T. 2006. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst, 98: 545-556. (Pubitemid 43898818)
37. Kong, D, Okamura, M, Yoshimi, H, and, Yamori, T. 2009. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. Eur J Cancer, 45: 857-865.
38. Kong, D, and, Yamori, T. 2007. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci, 98: 1638-1642. (Pubitemid 47308463)
39. Kong, D, and, Yamori, T. 2008. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci, 99: 1734-1740.
40. Scotti, M L, Langenheim, J F, Tomblyn, S, Springs, A E, and, Chen, W Y. 2008. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat, 111: 241-250.
41. Ozbay, T, Durden, D L, Liu, T, ORegan, R M, and, Nahta, R. 2010. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol, 65: 697-706.